随着RNAi癌症疗法的早期发展,Silexion治疗机构报告季度亏损,其库存接近2.81美元。 Silexion Therapeutics reported a quarterly loss, with its stock near $2.81, as it advances RNAi cancer therapies in early development.

Silexion Therapeutics 报告季度每股亏损 2.88 美元，其股价收于 2.81 美元，因交易量低于平均水平而下跌 0.01 美元。 Silexion Therapeutics reported a quarterly loss of $2.88 per share, with its stock closing at $2.81, down $0.01 on lighter-than-average trading volume. 该公司价值877万美元,仍处于早期开发阶段,没有商业产品,利用LODER平台侧重于基于RNAi的癌症治疗。 The company, valued at $8.77 million, remains in early development with no commercial products, focusing on RNAi-based cancer therapies using its LODER platform. 其主要候选人SiG12D-LODER已完成了第一阶段的胰腺癌试验,而前列腺-LODER和GBM-LODER处于临床前阶段。 Its lead candidate, SiG12D-LODER, has completed Phase I trials for pancreatic cancer, while Prostate-LODER and GBM-LODER are in pre-clinical stages. 分析师的评分有好有坏,结果形成共识“等待”和平均价格目标75.00美元。 Analysts maintain a mixed rating, resulting in a consensus "Hold" and a $75.00 average price target.